PriceList for Pregabalin Effects - Dabigatran Etexilate Mesylate – CPF
PriceList for Pregabalin Effects - Dabigatran Etexilate Mesylate – CPF Detail:
Description
Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active prodrug of Dabigatran. Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.
Background
Description: IC50 Value: 4.5nM (Ki); 10nM(Thrombin-induced platelet aggregation) [1] Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) undergoing advanced clinical development as its orally active prodrug,dabigatran etexilate. in vitro: Dabigatran selectively and reversibly inhibited human thrombin(Ki: 4.5 nM) as well as thrombin-induced platelet aggregation (IC(50): 10 nM), while showing no inhibitory effect on other platelet-stimulating agents.Thrombin generation in platelet-poor plasma (PPP), measured as the endogenous thrombin potential (ETP) was inhibited concentration-dependently (IC(50): 0.56 microM). Dabigatran demonstrated concentration-dependent anticoagulant effects in various species in vitro, doubling the activated partial thromboplastin time (aPTT), prothrombin time (PT) and ecarin clotting time (ECT) in human PPP at concentrations of 0.23, 0.83 and 0.18 microM, respectively [1]. in vivo: Dabigatran prolonged the aPTT dose-dependently after intravenous administration in rats (0.3, 1 and 3 mg/kg) and rhesus monkeys (0.15, 0.3 and 0.6 mg/kg). Dose- and time-dependent anticoagulant effects were observed with dabigatran etexilate administered orally to conscious rats (10, 20 and 50 mg/kg) or rhesus monkeys (1, 2.5 or 5 mg/kg), with maximum effects observed between 30 and 120 min after administration, respectively [1]. Patients treated with dabigatran etexilate experienced fewer ischaemic strokes (3.74 dabigatran etexilate vs 3.97 warfarin) and fewer combined intracranial haemorrhages and haemorrhagic strokes (0.43 dabigatran etexilate vs 0.99 warfarin) per 100 patient-years [2]. Clinical trial: An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients . Phase1
Storage
| Powder |
-20°C |
3 years |
|
4°C |
2 years | |
| In solvent |
-80°C |
6 months |
|
-20°C |
1 month |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase |
| NCT02170792 | Boehringer Ingelheim | Healthy | February 2001 |
Phase 1 |
| NCT02170974 | Boehringer Ingelheim | Healthy | July 2004 |
Phase 1 |
| NCT02170831 | Boehringer Ingelheim | Healthy | May 1999 |
Phase 1 |
| NCT02170805 | Boehringer Ingelheim | Healthy | April 2001 |
Phase 1 |
| NCT02170610 | Boehringer Ingelheim | Healthy | March 2002 |
Phase 1 |
| NCT02170909 | Boehringer Ingelheim | Healthy | December 2004 |
Phase 1 |
| NCT02171000 | Boehringer Ingelheim | Healthy | April 2005 |
Phase 1 |
| NCT02170844 | Boehringer Ingelheim | Healthy | June 2004 |
Phase 1 |
| NCT02170584 | Boehringer Ingelheim | Healthy | January 2001 |
Phase 1 |
| NCT02170935 | Boehringer Ingelheim | Venous Thromboembolism | April 2002 |
Phase 2 |
| NCT02170636 | Boehringer Ingelheim | Healthy | January 2002 |
Phase 1 |
| NCT02170766 | Boehringer Ingelheim | Healthy | October 2000 |
Phase 1 |
| NCT02171442 | Boehringer Ingelheim | Healthy | April 2002 |
Phase 1 |
| NCT02170896 | Boehringer Ingelheim | Healthy | October 2001 |
Phase 1 |
| NCT02173730 | Boehringer Ingelheim | Healthy | November 2002 |
Phase 1 |
| NCT02170623 | Boehringer Ingelheim | Healthy | February 2002 |
Phase 1 |
| NCT02170116 | Boehringer Ingelheim | Healthy | November 1998 |
Phase 1 |
| NCT02170597 | Boehringer Ingelheim | Healthy | August 2003 |
Phase 1 |
| NCT01225822 | Boehringer Ingelheim | Venous Thromboembolism | November 2002 |
Phase 2 |
| NCT02170701 | Boehringer Ingelheim | Venous Thromboembolism | October 2000 |
Phase 2 |
| NCT02170740 | Boehringer Ingelheim | Healthy | November 1999 |
Phase 1 |
| NCT02170922 | Boehringer Ingelheim | Healthy | July 1999 |
Phase 1 |
Chemical structure
Proposal 18 Quality Consistency Evaluation projects which have approved 4, and 6 projects are under approving.
Advanced international quality management system has laid solid foundation for sales.
Quality supervision runs through the whole life cycle of the product to ensure the quality and therapeutic effect.
Professional Regulatory Affairs team supports the quality demands during the application and registration.
VIEW MORE
VIEW MORE
International cooperation
Domestic cooperation
Product detail pictures:
Related Product Guide:
All we do is always associated with our tenet " Customer first, Trust first, devoting on the food packaging and environmental protection for PriceList for Pregabalin Effects - Dabigatran Etexilate Mesylate – CPF , The product will supply to all over the world, such as: Costa rica, Belize, Munich, Corporate goal: Customers' satisfaction is our goal, and sincerely hope to establish long-terms stable cooperative relations with customers to jointly develop the market. Building brilliant tomorrow together!Our company regards "reasonable prices, efficient production time and good after-sales service" as our tenet. We hope to cooperate with more customers for mutual development and benefits. We welcome potential buyers to contact us.
By Myrna from Ethiopia - 2018.09.21 11:01
The company can think what our think, the urgency of urgency to act in the interests of our position, can be said this is a responsible company, we had a happy cooperation!
By King from Turkey - 2018.09.19 18:37
Products categories
-
China Wholesale Rosuvastatin Manufacturer Facto...
-
Factory made hot-sale Nikita Pitavastatin - Le...
-
Cheapest Factory Celecoxib Manufacturer - Pita...
-
8 Year Exporter Doxycycline Mono For Sinus Infe...
-
8 Year Exporter Doxycycline Monohydrate 100mg F...
-
Well-designed Ticagrelor 60 Mg - Niraparib 103...